◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Roivant Sciences Ltd (ROIV) EBITDA 2019–TTM

Name: Roivant Sciences Ltd (ROIV) ebitda history 2019-TTM
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-09-19

Roivant Sciences Ltd annual ebitda for fiscal 2026 was -$261 million, an increase of 60.9% from -$668 million in fiscal 2025. All figures are reported results from public filings — no estimates or projections.

ROIV Annual EBITDA

EBITDA (annual)	TTM → 2026-06-30	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31	2021-03-31	2020-03-31	2019-03-31
EBITDA	—	($261M)	($668M)	$4.6B	($838M)	($911M)	($896M)	($553M)	$138M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ROIV Quarterly EBITDA

EBITDA (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
EBITDA	—	$455M	($290M)	($158M)	($268M)	($202M)	($232M)	($223M)	($220M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

EBITDA at Comparable Companies

RVMD EBITDA — Revolution Medicines Inc
RPRX EBITDA — Royalty Pharma Plc
ALNY EBITDA — Alnylam Pharmaceuticals Inc
INSM EBITDA — Insmed Inc
JAZZ EBITDA — Jazz Pharmaceuticals PLC

More ROIV metrics: Revenue · Gross Profit · Operating Income · Net Income · EPS · Free Cash Flow · Shares Outstanding

All ROIV financial statements → Interactive ROIV charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.